# Trevarx Biomedical

Source: https://onco.cc/companies/trevarx-biomedical/  
OnCo record `trevarx-biomedical` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Trevarx Biomedical is a Philadelphia company attaching a radioactive atom to a PARP inhibitor so that radiation is released right at a tumour cell's DNA. Its first drug, AlphaPARP, is being prepared for ovarian cancer.

## Summary

Trevarx Biomedical, Inc. is building a DNA-directed alpha radiopharmaceutical platform. Its first therapeutic, AlphaPARP, is astatine-211 attached to a PARP inhibitor backbone (Parthanatine), designed to bind activated PARP1 at sites of tumour DNA damage so that alpha energy is deposited next to the DNA; the company says it is seeking a USD 35 million Series A. A 2026 National Cancer Institute SBIR award funds preparation for a phase 1 IND of the agent in ovarian cancer, and the award abstract describes a companion PET imaging agent that binds the same target for patient selection.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Trevarx Biomedical, Inc.; Trevarx
- HQ: Philadelphia, PA
- Type: radiopharma
- Website: https://www.trevarx.com/

## Notes

- Company website and the NIH RePORTER record read on 4 November 2026. Founding year not stated on the website.

## Sources

- Official website: https://www.trevarx.com/
- NIH RePORTER: award 1R44CA310342-01A1: https://reporter.nih.gov/project-details/11408032

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- fronts: [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- technologies: [Astatine-211 alpha therapy](https://onco.cc/technologies/astatine-211-alpha-therapy/), [Targeted alpha therapy](https://onco.cc/technologies/targeted-alpha-therapy/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [AlphaPARP](https://onco.cc/drugs/alphaparp/)

---
JSON: https://onco.cc/api/v1/entities/trevarx-biomedical.json